Protocol Ledger

NCT04733118 · Phase II · ACTIVE NOT RECRUITING

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Interventional Phase II clinical trial protocol NCT04733118 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-05 Enrollment: 393 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04733118
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)393 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04733118
Protocol FieldVerified Registry Value
NCT IdentifierNCT04733118
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment393 participants (ACTUAL)
Registered Start Date2021-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04733118
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria di ParmaParma, ItalyOpen Hospital Dossier ->
Hospital Universitario Reina SofiaCórdoba, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI